Biochemistry & Analytical Biochemistry

Papillary thyroid carcinoma during etanercept therapy in a patient with psoriatic arthritis

International Conference on Clinical Chemistry & Laboratory Medicine

October 17-18, 2016 Chicago, USA

Ilker Ilhanli

Giresun University, Turkey

Scientific Tracks Abstracts: Biochem Anal Biochem

Abstract:

In recent years usage of the Tumor necrosis alpha blockers (Anti-TNFα) in rheumatologic diseases has been increased and their efficacy has been proved. Etanercept is a fusion protein resembling TNF receptors type-II, which acts by blocking circulating TNF and lymphotoxin-a. It is approved for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, moderate to severe plaque psoriasis and severely active polyarticular juvenile idiopathic arthritis in children aged 2 years and older. While the importance of these drugs is folding up, some questions are appearing in the minds, like whether they lead or facilitate the malign process. Thyroid cancer is the most common malignant tumor of the endocrine system. The incidence of thyroid cancers is increasing worldwide. Some somatic oncogene mutations (BRAF, NRAS, HRAS, KRAS) as well as gene translocations (RET/PTC, PAX8/PPARgamma) have been associated with the development of thyroid cancer. The most frequent type of thyroid malignancy is papillary carcinoma. Here we reported a 52 years old female patient who was diagnosed as papillary thyroid carcinoma while she was using etanercept for psoriatic arthritis.

Biography :

Ilker Ilhanli is an Assistant Professor and is graduated from Ondokuz Mayis University School of Medicine in 2004. He has joined the Giresun University, Turkey in 2011 and established the Department of Physical Medicine and Rehabilitation. He has authored/co-authored more than 50 scientific publications and has been part of many program committees and organization bodies (journals and conferences). He has international books about cultural adaptation studies and vibration at workplace. He is the Vice-President of Internal Medicine Sciences, Vice-Director of Traditional and Complementary Medicine Research Center and Institute of Health Sciences.

Email: ilkerilhanli@hotmail.com